Reactive nitrogen species scavenging, rather than nitric oxide inhibition, protects from articular cartilage damage in rat zymosan-induced arthritis

Br J Pharmacol. 2004 Jan;141(1):172-82. doi: 10.1038/sj.bjp.0705600. Epub 2003 Dec 8.

Abstract

1. The contribution of nitric oxide (NO) and peroxynitrite (PN) to inflammation in a zymosan-induced (1 mg, intra-articular, i.art.) rat model of arthritis was assessed by histopathology and by measuring the glycosaminoglycan (GAG) content of the articular cartilage. 2. Progression of the chronic synovitis in zymosan-induced arthritis (ZYA) was associated with increased nitrite and nitrotyrosine (3-NT) levels in the joint exudates that paralleled a progressive loss of the GAG content. An increase in 3-NT was also observed after i.art. PN. 3. The nonselective nitric oxide synthase (NOS) inhibitor l-N(G)-nitroarginine methyl ester (25-75 mg x kg(-1)day(-1)) or the selective inducible NOS inhibitor aminoguanidine (50-100 mg x kg(-1)day(-1)) given 1 h before (prophylactic) or 3 days after (therapeutic) injection of the zymosan ameliorated the synovitis, but worsened the GAG loss, as measured at the end of the experiment (day 7). 4. The PN scavenger uric acid (100-250 mg x kg(-1) i.p. four times daily) given prophylactically until the end of the experiment (day 14), in a dose compatible with its PN scavenging activity, significantly decreased both the synovitis and the GAG loss. 5. In conclusion, PN formation is associated with cartilage damage in addition to proinflammatory activity in ZYA. NOS inhibitors and a PN scavenger were able to reduce the cellular infiltration, while displaying opposite effects on cartilage homeostasis either by enhancing or ameliorating the damage, respectively.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Arthritis, Experimental / chemically induced*
  • Cartilage, Articular / drug effects*
  • Cartilage, Articular / pathology
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Free Radical Scavengers / pharmacology
  • Free Radical Scavengers / therapeutic use*
  • Glycosaminoglycans / antagonists & inhibitors
  • Glycosaminoglycans / chemistry
  • Glycosaminoglycans / metabolism
  • Guanidines / pharmacology
  • Guanidines / therapeutic use
  • Injections, Intra-Articular
  • Injections, Intraperitoneal
  • Male
  • NG-Nitroarginine Methyl Ester / administration & dosage
  • NG-Nitroarginine Methyl Ester / pharmacology
  • NG-Nitroarginine Methyl Ester / therapeutic use
  • Nitric Oxide / adverse effects*
  • Nitric Oxide / antagonists & inhibitors
  • Nitric Oxide / chemistry
  • Nitric Oxide Synthase / antagonists & inhibitors
  • Nitric Oxide Synthase / pharmacology
  • Nitric Oxide Synthase / therapeutic use
  • Nitrites / antagonists & inhibitors
  • Nitrites / chemistry
  • Peroxynitrous Acid / administration & dosage
  • Peroxynitrous Acid / pharmacology
  • Rats
  • Rats, Wistar
  • Reactive Nitrogen Species / antagonists & inhibitors*
  • Reactive Nitrogen Species / therapeutic use
  • Synovial Fluid / chemistry
  • Synovial Fluid / drug effects
  • Synovial Fluid / metabolism
  • Synovial Membrane / drug effects
  • Synovial Membrane / physiopathology
  • Synovial Membrane / ultrastructure
  • Synovitis / chemically induced
  • Synovitis / drug therapy
  • Tyrosine / analogs & derivatives*
  • Tyrosine / antagonists & inhibitors
  • Tyrosine / biosynthesis
  • Tyrosine / chemistry
  • Uric Acid / administration & dosage
  • Uric Acid / blood
  • Uric Acid / pharmacology
  • Zymosan / administration & dosage
  • Zymosan / adverse effects*

Substances

  • Free Radical Scavengers
  • Glycosaminoglycans
  • Guanidines
  • Nitrites
  • Reactive Nitrogen Species
  • Peroxynitrous Acid
  • Uric Acid
  • Nitric Oxide
  • 3-nitrotyrosine
  • Tyrosine
  • Zymosan
  • Nitric Oxide Synthase
  • pimagedine
  • NG-Nitroarginine Methyl Ester